Table 1. Incidence of GATA-3 and CDX-2 positivity in breast, GI and lung cancer.

IHC	Breast cancer	GI malignancies	Lung
GATA-3	80–90% [9]	<7% [9]	<10% [9]
CDX -2	Not seen	100% – Colorectal >50% – gastric adenocarcinoma >33% – pancreatobiliary tract carcinomas. [10]	40% – 50% of the non-mucinous adenocarcinomas (but along with TTF-1) [11]

GI – Gastrointestinal;

TTF-1 – Thyroid transcription factor-1.